A breakthrough for those struggling with obesity and heart disease has been announced by the FDA, with the approval of Wegovy for a new use: reducing the risks of heart attacks, strokes, and cardiovascular-related death in adults who are overweight or obese.
Wegovy, a popular weight loss drug, has shown promising results in a study of over 17,000 adults aged 45 and older. Participants who received Wegovy had a lower rate of heart attacks, strokes, and cardiovascular-related deaths compared to those who received a placebo. This has led to the FDA’s decision to expand the medication’s use.
The drug’s maker, Novo Nordisk, has not only received approval in the U.S., but has also applied for an expanded label in the European Union. This could potentially broaden insurance coverage for the use of Wegovy in high-risk individuals.
While the exact mechanism behind Wegovy’s heart benefits is still unclear, experts believe that treating obesity seriously in patients with a high burden of disease can lead to positive outcomes. Dr. Melanie Jay, director of the N.Y.U. Langone Comprehensive Program on Obesity, highlighted the potential benefits of addressing obesity in this population.
The approval of Wegovy for reducing the risks of heart attacks, strokes, and cardiovascular-related death in adults with heart disease who are overweight or obese marks a significant advancement in the fight against obesity-related health issues. The availability of this medication could make a life-saving difference for many individuals struggling with weight management and heart health.
“Zombie enthusiast. Subtly charming travel practitioner. Webaholic. Internet expert.”